These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8869047)

  • 1. [Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment].
    Cupissol D; Brès J; Gestin-Boyer C; Nouguier-Soulé J; Vian L; Tep A; Nouguier J
    Bull Cancer; 1996 Aug; 83(8):664-76. PubMed ID: 8869047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump].
    Gestin-Boyer C; René C; Cupissol D; Tep A; Bressolle F; Bres J; Brun S; Serrou B; Pujol H
    C R Seances Soc Biol Fil; 1989; 183(3):263-8. PubMed ID: 2532561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
    Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M
    Gan To Kagaku Ryoho; 1996 Nov; 23(13):1740-6. PubMed ID: 8937483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of long-term oral amiodarone therapy.
    Pollak PT; Bouillon T; Shafer SL
    Clin Pharmacol Ther; 2000 Jun; 67(6):642-52. PubMed ID: 10872646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers.
    Schaefer PL; Marks RS; Mahoney MR; Sloan JA; Bauman MD; Tazelaar HD; Kugler JW; Mailliard JA; Ebbert LP; Wiesenfeld M
    Am J Clin Oncol; 2003 Jun; 26(3):236-40. PubMed ID: 12796591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Low-dose CDDP and 5-FU for head and neck cancer patients].
    Fujii M; Kanke M; Tomita T
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
    Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
    Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.
    Rowinsky EK; Jiroutek M; Bonomi P; Johnson D; Baker SD
    Clin Cancer Res; 1999 Apr; 5(4):767-74. PubMed ID: 10213211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
    Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.